Northern Trust
CDTX

Northern Trust’s Cidara Therapeutics CDTX Stock Holding History

Northern Trust’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-179,081
Closed -$39.6M – 4422
2025
Q4 		$39.6M Buy
179,081
+28,913
+19% +$4.67M 0.01% 1258
2025
Q3 		$14.4M Buy
150,168
+4,997
+3% +$319K ﹤0.01% 1900
2025
Q2 		$7.07M Buy
145,171
+111,611
+333% +$2.68M ﹤0.01% 2264
2025
Q1 		$723K Sell
33,560
-397
-1% -$8.82K ﹤0.01% 3415
2024
Q4 		$913K Buy
33,957
+2,170
+7% +$35.3K ﹤0.01% 3434
2024
Q3 		$342K Buy
+31,787
New +$382K ﹤0.01% 3695
2024
Q2 		– Sell
-8,018
Closed -$148K – 4425
2024
Q1 		$148K Sell
8,018
-11
-0.1% -$158 ﹤0.01% 3978
2023
Q4 		$127K Buy
8,029
+1,631
+25% +$26.2K ﹤0.01% 4049
2023
Q3 		$121K Hold
6,398
– – ﹤0.01% 3962
2023
Q2 		$145K Buy
6,398
+801
+14% +$18.8K ﹤0.01% 3938
2023
Q1 		$142K Buy
5,597
+322
+6% +$9.14K ﹤0.01% 3977
2022
Q4 		$79.8K Hold
5,275
– – ﹤0.01% 4167
2022
Q3 		$66K Buy
5,275
+355
+7% +$4.9K ﹤0.01% 4244
2022
Q2 		$48K Hold
4,920
– – ﹤0.01% 4420
2022
Q1 		$82K Sell
4,920
-605
-11% -$10.3K ﹤0.01% 4407
2021
Q4 		$140K Buy
5,525
+2,039
+58% +$63.5K ﹤0.01% 4317
2021
Q3 		$156K Sell
3,486
-135
-4% -$5.13K ﹤0.01% 4266
2021
Q2 		$146K Sell
3,621
-15,099
-81% -$639K ﹤0.01% 4258
2021
Q1 		$996K Sell
18,720
-781
-4% -$38.6K ﹤0.01% 3587
2020
Q4 		$780K Buy
19,501
+254
+1% +$12.6K ﹤0.01% 3602
2020
Q3 		$1.1M Buy
19,247
+13,346
+226% +$943K ﹤0.01% 3359
2020
Q2 		$436K Buy
5,901
+3,480
+144% +$226K ﹤0.01% 3590
2020
Q1 		$120K Buy
2,421
+959
+66% +$57.5K ﹤0.01% 3783
2019
Q4 		$112K Buy
1,462
+207
+16% +$9.48K ﹤0.01% 3914
2019
Q3 		$50K Sell
1,255
-47
-4% -$1.58K ﹤0.01% 4048
2019
Q2 		$44K Sell
1,302
-179
-12% -$7.44K ﹤0.01% 4098
2019
Q1 		$79K Sell
1,481
-688
-32% -$37.7K ﹤0.01% 3969
2018
Q4 		$102K Buy
2,169
+13
+0.6% +$928 ﹤0.01% 3918
2018
Q3 		$190K Buy
2,156
+287
+15% +$25.3K ﹤0.01% 3880
2018
Q2 		$195K Buy
1,869
+90
+5% +$8.5K ﹤0.01% 3866
2018
Q1 		$142K Buy
1,779
+901
+103% +$123K ﹤0.01% 3890
2017
Q4 		$119K Sell
878
-29
-3% -$4.4K ﹤0.01% 3937
2017
Q3 		$147K Sell
907
-1
-0.1% -$142 ﹤0.01% 3865
2017
Q2 		$137K Sell
908
-4,719
-84% -$652K ﹤0.01% 3902
2017
Q1 		$878K Buy
5,627
+331
+6% +$58.1K ﹤0.01% 3389
2016
Q4 		$1.1M Buy
5,296
+508
+11% +$106K ﹤0.01% 3323
2016
Q3 		$1.1M Sell
4,788
-9
-0.2% -$2.08K ﹤0.01% 3319
2016
Q2 		$989K Buy
4,797
+2,286
+91% +$553K ﹤0.01% 3350
2016
Q1 		$638K Buy
2,511
+4
+0.2% +$922 ﹤0.01% 3396
2015
Q4 		$860K Buy
2,507
+156
+7% +$46.8K ﹤0.01% 3369
2015
Q3 		$599K Buy
+2,351
New +$672K ﹤0.01% 3452

Northern Trust's CDTX Position: Q1 2026 in Review

Northern Trust sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 179,081 shares — an estimated $39.6M sold.

Northern Trust first reported a position in CDTX in Q3 2015 and held it in 41 quarters. The position peaked at $39.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • Northern Trust reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Northern Trust sold 179,081 Cidara Therapeutics shares in Q1 2026, an estimated $39.6M.
  • Northern Trust first reported a position in Cidara Therapeutics in Q3 2015 and held it in 41 quarters.
  • Northern Trust's Cidara Therapeutics position peaked at $39.6M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.